Conference Coverage
VIDEO: IL-17 antagonists continue reshaping psoriasis therapy in 2016
IL-17 antagonists should continue to reshape psoriasis therapy in 2016, Dr. Craig Leonardi predicted.
Ixekizumab is under FDA review for psoriasis and a decision is expected within the first quarter of 2016, according to a spokesperson for Eli Lilly.
Dr. Leonardi is a recipient of research grants from well over a dozen pharmaceutical companies and is a consultant to and/or member of the speakers bureaus for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Janssen, Eli Lilly, Leo, Novartis, Pfizer, Sandoz, UCB, and Vitae.
SDEF and this news organization are owned by the same parent company.
